JBI-589
Based on 1 Customer Validation
JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 2308504-22-3
- Formula: C29H28FN5O
- Molecular Weight:481.56
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
JBI-589 (1 μM, 2 h) significantly downregulates the expression of CXCR2 on neutrophils and reduces their migration induced by CXCL1 in vitro, with no effect on the suppressive activity of Ly6G cells generated from HPCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Phorbol 12-myristate 13-acetate (HY-18739)-induced Mouse neutrophils
-
Concentration:0.25-1 μM
-
Incubation Time:4 h
-
Result:Inhibited the citrullination of histone H3 in Phorbol 12-myristate 13-acetate (HY-18739)-induced mouse neutrophils in a dose-dependent manner, with no apparent toxicity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LL2 tumor C57BL/6 mouse model; B16F10 tumor C57BL/6 mouse model
-
Dosage:50 mg/kg
-
Administration:Oral gavage (p.o.), twice daily
-
Result:Led to a significant downregulation of CXCR2 receptor expression in Ly6G cells of the mice, while CXCR4 receptor expression remained unchanged. Had no effect on the cell counts of bone marrow cells, CD8 T cells, and NK cells in tumor-bearing mice model.
Chemical Information
-
CAS No. 2308504-22-3
-
Appearance Solid
-
Molecular Weight 481.56
-
Formula C29H28FN5O
-
Color Light yellow to yellow
-
SMILES
CC(N1C(C=C(C=C1)C(N2C[C@@H](CCC2)N)=O)=N3)=C3C4=CC5=CC=CC=C5N4CC6=CC=C(C=C6)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (207.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82(19):3561-3572. [Content Brief]
[2]. Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13(1):3189. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0766 mL | 10.3829 mL | 20.7658 mL | 51.9146 mL |
| 5 mM | 0.4153 mL | 2.0766 mL | 4.1532 mL | 10.3829 mL | |
| 10 mM | 0.2077 mL | 1.0383 mL | 2.0766 mL | 5.1915 mL | |
| 15 mM | 0.1384 mL | 0.6922 mL | 1.3844 mL | 3.4610 mL | |
| 20 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL | 2.5957 mL | |
| 25 mM | 0.0831 mL | 0.4153 mL | 0.8306 mL | 2.0766 mL | |
| 30 mM | 0.0692 mL | 0.3461 mL | 0.6922 mL | 1.7305 mL | |
| 40 mM | 0.0519 mL | 0.2596 mL | 0.5191 mL | 1.2979 mL | |
| 50 mM | 0.0415 mL | 0.2077 mL | 0.4153 mL | 1.0383 mL | |
| 60 mM | 0.0346 mL | 0.1730 mL | 0.3461 mL | 0.8652 mL | |
| 80 mM | 0.0260 mL | 0.1298 mL | 0.2596 mL | 0.6489 mL | |
| 100 mM | 0.0208 mL | 0.1038 mL | 0.2077 mL | 0.5191 mL |
JBI-589 Related Classifications
HY-153450 Related Classifications
Powered by Bioz